733 related articles for article (PubMed ID: 33248320)
21. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
[TBL] [Abstract][Full Text] [Related]
22. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
[TBL] [Abstract][Full Text] [Related]
23. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR
J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456
[TBL] [Abstract][Full Text] [Related]
24. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
[No Abstract] [Full Text] [Related]
26. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Luo X; Zhou Z; Zeng X; Peng L; Liu Q
Front Public Health; 2022; 10():985834. PubMed ID: 36211665
[TBL] [Abstract][Full Text] [Related]
27. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M; Shao T; Shao H; Zhou C; Tang W
BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
[TBL] [Abstract][Full Text] [Related]
28. First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World Data.
Jeon Y; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
Cancer Res Treat; 2024 Jan; 56(1):61-69. PubMed ID: 37448121
[TBL] [Abstract][Full Text] [Related]
29. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
30. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
[TBL] [Abstract][Full Text] [Related]
31. Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC.
Stinchcombe TE; Doebele RC; Wang X; Gerber DE; Horn L; Camidge DR
J Thorac Oncol; 2021 Jan; 16(1):156-161. PubMed ID: 33039599
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory
Gettinger SN; Huber RM; Kim DW; Bazhenova L; Hansen KH; Tiseo M; Langer CJ; Paz-Ares Rodríguez LG; West HL; Reckamp KL; Weiss GJ; Smit EF; Hochmair MJ; Kim SW; Ahn MJ; Kim ES; Groen HJM; Pye J; Liu Y; Zhang P; Vranceanu F; Camidge DR
JTO Clin Res Rep; 2022 Sep; 3(9):100385. PubMed ID: 36065449
[TBL] [Abstract][Full Text] [Related]
33. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
Ahn MJ; Kim HR; Yang JCH; Han JY; Li JY; Hochmair MJ; Chang GC; Delmonte A; Lee KH; Campelo RG; Gridelli C; Spira AI; Califano R; Griesinger F; Ghosh S; Felip E; Kim DW; Liu Y; Zhang P; Popat S; Camidge DR
Clin Lung Cancer; 2022 Dec; 23(8):720-730. PubMed ID: 36038416
[TBL] [Abstract][Full Text] [Related]
35. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Gadgeel SM; Shaw AT; Govindan R; Gandhi L; Socinski MA; Camidge DR; De Petris L; Kim DW; Chiappori A; Moro-Sibilot DL; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; Yang JC; Han JY; Bordogna W; Golding S; Zeaiter A; Ou SI
J Clin Oncol; 2016 Dec; 34(34):4079-4085. PubMed ID: 27863201
[TBL] [Abstract][Full Text] [Related]
36. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
[TBL] [Abstract][Full Text] [Related]
37. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
39. ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
Noé J; Lovejoy A; Ou SI; Yaung SJ; Bordogna W; Klass DM; Cummings CA; Shaw AT
J Thorac Oncol; 2020 Apr; 15(4):601-608. PubMed ID: 31712133
[TBL] [Abstract][Full Text] [Related]
40. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
